Fact CheckerSign in

NCT07265076Not yet recruiting

Role of Omega-6 Fatty Acids in Hepatocellular Carcinoma Development.

Study of Omega-6 Fatty Acids in Patients With Hepatocellular Carcinoma

Source: ClinicalTrials.gov · Last updated 4 Dec 2025

Brief summary (registry, in English)

This observational study investigates the association between serum Omega-6 fatty acids and hepatocellular carcinoma development. Adult HCC patients and age - and gender matched healthy controls will be included. Serum Omega-6 levels will be compared between groups to explore potential correlations with disease presence and severity .

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
23 Nov 2025
Start date
1 Dec 2025
Primary completion date
30 Jun 2026
Lead sponsor
Sohag University
NCT number
NCT07265076

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 1 Dec 2025 to the primary completion date, 30 Jun 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • History of chronic inflammatory (except for liver cirrhosis or HCC) or autoimmune diseases.
  • Presence of other types of cancer.
  • presence of severe comorbid condition.
    • \-

Other

  • Current use of omega-6 or omega-3 fatty acid supplements.
  • Pregnant or lactating women.

Who the study is looking for

  • 1\. Adults aged 18 years and above. 2. Patients with hepatocellular carcinoma (confirmed clinically, laboratory, radiologically, or histopathologically).
    • 3\. Ability and willingness to provide informed written consent. 4. For healthy controls: individuals without liver disease or history of malignancy, matched by age and gender.
    • 5\. For cirrhotic controls: patients with liver cirrhosis without evidence of any malignancy, matched by age and gender.

Age in the registry: 18 years to 50 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.